{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:39:21Z","timestamp":1792787961540,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Nanjing Health Science Technology Development Project","award":["No. YKK2470"],"award-info":[{"award-number":["No. YKK2470"]}]},{"name":"the Nanjing Health Science Technology Development Project","award":["No. YKK2470"],"award-info":[{"award-number":["No. YKK2470"]}]},{"name":"the Nanjing Health Science Technology Development Project","award":["No. YKK2470"],"award-info":[{"award-number":["No. YKK2470"]}]},{"name":"the Nanjing Health Science Technology Development Project","award":["No. YKK2470"],"award-info":[{"award-number":["No. YKK2470"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-03882-3","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T07:06:34Z","timestamp":1749798394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hepatic artery infusion chemotherapy plus an immune checkpoint inhibitor and lenvatinib for the treatment of biliary tract carcinoma"],"prefix":"10.1186","volume":"23","author":[{"given":"Junying","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhe","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaojun","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"issue":"10272","key":"3882_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397(10272):428\u201344.","journal-title":"Lancet"},{"issue":"3","key":"3882_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"3882_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, et al. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127\u201340.","journal-title":"Ann Oncol"},{"issue":"24","key":"3882_CR4","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1200\/JCO.21.02576","volume":"40","author":"AJ Scott","year":"2022","unstructured":"Scott AJ, Sharman R, Shroff RT. Precision medicine in biliary tract Cancer. J Clin Oncol. 2022;40(24):2716\u201334.","journal-title":"J Clin Oncol"},{"key":"3882_CR5","doi-asserted-by":"crossref","unstructured":"Queiroz MM, Lima NF Jr., Biachi de Castria T. Immunotherapy and targeted therapy for advanced biliary tract cancer: adding new flavors to the pizza. Cancers (Basel). 2023;15(7).","DOI":"10.3390\/cancers15071970"},{"key":"3882_CR6","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2147\/OTT.S269671","volume":"14","author":"PK Seesaha","year":"2021","unstructured":"Seesaha PK, Wang KX, Wang GQ, et al. Current progress and future perspectives of immune checkpoint inhibitors in biliary tract Cancer. Onco Targets Ther. 2021;14:1873\u201382.","journal-title":"Onco Targets Ther"},{"issue":"8","key":"3882_CR7","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/ijc.33013","volume":"147","author":"SA Piha-Paul","year":"2020","unstructured":"Piha-Paul SA, Oh DY, Ueno M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020;147(8):2190\u201398.","journal-title":"Int J Cancer"},{"issue":"8","key":"3882_CR8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2468-1253(19)30086-X","volume":"4","author":"M Ueno","year":"2019","unstructured":"Ueno M, Ikeda M, Morizane C, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol. 2019;4(8):611\u201321.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"3882_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12943-018-0801-5","volume":"17","author":"Q Jiao","year":"2018","unstructured":"Jiao Q, Bi L, Ren Y, Song S, Wang Q, Wang YS. Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Mol Cancer. 2018;17(1):36.","journal-title":"Mol Cancer"},{"issue":"1","key":"3882_CR10","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1186\/s12885-020-07365-4","volume":"20","author":"M Ueno","year":"2020","unstructured":"Ueno M, Ikeda M, Sasaki T, et al. Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results. BMC Cancer. 2020;20(1):1105.","journal-title":"BMC Cancer"},{"issue":"1","key":"3882_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/hep.32548","volume":"77","author":"J Zhou","year":"2023","unstructured":"Zhou J, Sun Y, Zhang W, et al. Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Hepatology. 2023;77(1):65\u201376.","journal-title":"Hepatology"},{"issue":"1","key":"3882_CR12","doi-asserted-by":"publisher","first-page":"e1483","DOI":"10.1002\/cti2.1483","volume":"13","author":"M Zhou","year":"2024","unstructured":"Zhou M, Jin Y, Zhu S, et al. A phase II study to evaluate the safety and efficacy of anlotinib combined with Toripalimab for advanced biliary tract cancer. Clin Transl Immunol. 2024;13(1):e1483.","journal-title":"Clin Transl Immunol"},{"key":"3882_CR13","doi-asserted-by":"publisher","first-page":"785535","DOI":"10.3389\/fonc.2022.785535","volume":"12","author":"Y Wang","year":"2022","unstructured":"Wang Y, Yang X, Wang D, et al. Lenvatinib beyond First-Line therapy in patients with advanced biliary tract carcinoma. Front Oncol. 2022;12:785535.","journal-title":"Front Oncol"},{"issue":"2","key":"3882_CR14","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3322\/caac.21759","volume":"73","author":"D Moris","year":"2023","unstructured":"Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 2023;73(2):198\u2013222.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3882_CR15","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1186\/s12885-024-12355-x","volume":"24","author":"Y Xiao","year":"2024","unstructured":"Xiao Y, Deng W, Luo L, et al. Beneficial effects of maintaining liver function during hepatic arterial infusion chemotherapy combined with tyrosine kinase and programmed cell death protein-1 inhibitors on the outcomes of patients with unresectable hepatocellular carcinoma. BMC Cancer. 2024;24(1):588.","journal-title":"BMC Cancer"},{"issue":"17","key":"3882_CR16","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.2217\/imt-2021-0192","volume":"13","author":"BJ Liu","year":"2021","unstructured":"Liu BJ, Gao S, Zhu X, et al. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma. Immunotherapy. 2021;13(17):1395\u2013405.","journal-title":"Immunotherapy"},{"issue":"6","key":"3882_CR17","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3892\/ol.2023.14121","volume":"26","author":"Z Li","year":"2023","unstructured":"Li Z, Xu Y, Qu W, et al. Efficacy and safety of hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and tyrosine kinase inhibitors in advanced hepatocellular carcinoma: A systematic review and meta\u2013analysis. Oncol Lett. 2023;26(6):534.","journal-title":"Oncol Lett"},{"issue":"8\u20139","key":"3882_CR18","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/1751-2980.13127","volume":"23","author":"N Zhang","year":"2022","unstructured":"Zhang N, Yu BR, Wang YX, et al. Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti-PD-1 immunotherapy for unresectable intrahepatic cholangiocarcinoma. J Dig Dis. 2022;23(8\u20139):535\u201345.","journal-title":"J Dig Dis"},{"issue":"9","key":"3882_CR19","first-page":"828","volume":"24","author":"Carcinoma","year":"2019","unstructured":"Carcinoma, CoEoBT. CSCO expert consensus on diagnosis and treatment of biliary tract cancer (2019). Chin Clin Oncol. 2019;24(9):828\u201338.","journal-title":"Chin Clin Oncol"},{"issue":"2","key":"3882_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"key":"3882_CR21","doi-asserted-by":"publisher","first-page":"1384314","DOI":"10.3389\/fmed.2024.1384314","volume":"11","author":"J Su","year":"2024","unstructured":"Su J, Liang Y, He X. Global, regional, and National burden and trends analysis of gallbladder and biliary tract cancer from 1990 to 2019 and predictions to 2030: a systematic analysis for the global burden of disease study 2019. Front Med (Lausanne). 2024;11:1384314.","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"3882_CR22","doi-asserted-by":"publisher","first-page":"100503","DOI":"10.1016\/j.esmoop.2022.100503","volume":"7","author":"O Mirallas","year":"2022","unstructured":"Mirallas O, Lopez-Valbuena D, Garcia-Illescas D, et al. Advances in the systemic treatment of therapeutic approaches in biliary tract cancer. ESMO Open. 2022;7(3):100503.","journal-title":"ESMO Open"},{"key":"3882_CR23","doi-asserted-by":"publisher","first-page":"175883592312250","DOI":"10.1177\/17588359231225040","volume":"16","author":"K Zheng","year":"2024","unstructured":"Zheng K, Wang X. Techniques and status of hepatic arterial infusion chemotherapy for primary hepatobiliary cancers. Ther Adv Med Oncol. 2024;16:17588359231225040.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"3882_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/sj.bjc.6605465","volume":"102","author":"WM Liu","year":"2010","unstructured":"Liu WM, Fowler DW, Smith P, Dalgleish AG. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer. 2010;102(1):115\u201323.","journal-title":"Br J Cancer"},{"key":"3882_CR25","doi-asserted-by":"publisher","first-page":"939249","DOI":"10.3389\/fonc.2022.939249","volume":"12","author":"L Zhang","year":"2022","unstructured":"Zhang L, Zhou C, Zhang S, et al. Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors. Front Oncol. 2022;12:939249.","journal-title":"Front Oncol"},{"issue":"3","key":"3882_CR26","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1159\/000505695","volume":"9","author":"H Deng","year":"2020","unstructured":"Deng H, Kan A, Lyu N, et al. Dual vascular endothelial growth factor receptor and fibroblast growth factor receptor Inhibition elicits antitumor immunity and enhances programmed cell Death-1 checkpoint Blockade in hepatocellular carcinoma. Liver Cancer. 2020;9(3):338\u201357.","journal-title":"Liver Cancer"},{"key":"3882_CR27","doi-asserted-by":"publisher","first-page":"598877","DOI":"10.3389\/fimmu.2020.598877","volume":"11","author":"SP Hack","year":"2020","unstructured":"Hack SP, Zhu AX, Wang Y. Augmenting anticancer immunity through combined targeting of angiogenic and PD-1\/PD-L1 pathways: challenges and opportunities. Front Immunol. 2020;11:598877.","journal-title":"Front Immunol"},{"key":"3882_CR28","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3389\/fonc.2013.00259","volume":"3","author":"M Cesca","year":"2013","unstructured":"Cesca M, Bizzaro F, Zucchetti M, Giavazzi R. Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents. Front Oncol. 2013;3:259.","journal-title":"Front Oncol"},{"key":"3882_CR29","doi-asserted-by":"publisher","first-page":"1260191","DOI":"10.3389\/fimmu.2024.1260191","volume":"15","author":"Y Huang","year":"2024","unstructured":"Huang Y, Du Z, Kan A, et al. Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma. Front Immunol. 2024;15:1260191.","journal-title":"Front Immunol"},{"key":"3882_CR30","doi-asserted-by":"publisher","first-page":"1397827","DOI":"10.3389\/fimmu.2024.1397827","volume":"15","author":"R Zhao","year":"2024","unstructured":"Zhao R, Zhou J, Miao Z, et al. Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma. Front Immunol. 2024;15:1397827.","journal-title":"Front Immunol"},{"key":"3882_CR31","doi-asserted-by":"publisher","first-page":"111642","DOI":"10.1016\/j.intimp.2024.111642","volume":"129","author":"T Zhang","year":"2024","unstructured":"Zhang T, Zhu C, Zhang N, et al. Lenvatinib combined with PD-1 inhibitor plus Gemox chemotherapy versus plus HAIC for advanced biliary tract cancer. Int Immunopharmacol. 2024;129:111642.","journal-title":"Int Immunopharmacol"},{"key":"3882_CR32","doi-asserted-by":"publisher","first-page":"1235724","DOI":"10.3389\/fimmu.2023.1235724","volume":"14","author":"Z Wei","year":"2023","unstructured":"Wei Z, Wang Y, Wu B, et al. Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma. Front Immunol. 2023;14:1235724.","journal-title":"Front Immunol"},{"issue":"11","key":"3882_CR33","first-page":"5455","volume":"13","author":"Z Lin","year":"2023","unstructured":"Lin Z, Chen D, Hu X, et al. Clinical efficacy of HAIC (FOLFOX) combined with lenvatinib plus PD-1 inhibitors vs. TACE combined with lenvatinib plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus and Arterioportal fistulas. Am J Cancer Res. 2023;13(11):5455\u201365.","journal-title":"Am J Cancer Res"},{"key":"3882_CR34","doi-asserted-by":"publisher","first-page":"1178428","DOI":"10.3389\/fonc.2023.1178428","volume":"13","author":"LW Lin","year":"2023","unstructured":"Lin LW, Ke K, Yan LY, Chen R, Huang JY. Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization. Front Oncol. 2023;13:1178428.","journal-title":"Front Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03882-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-03882-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03882-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T07:06:36Z","timestamp":1749798396000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-03882-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3882"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-03882-3","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]},"assertion":[{"value":"10 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study obtained approval from the Ethics Committee. All BTC patients or their families signed informed consent forms.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"233"}}